Cortalix, a Groningen-based biotech startup, has secured €1M in funding to enhance its single-domain antibody technology aimed at improving PET imaging diagnostics and cancer therapies. Launched in 2023, Cortalix specializes in the development of animal-free antibodies that are more efficient and stable compared to traditional ones. Collaborating with the University of Groningen and UMCG, it focuses on CAR-T cell therapy. CEO Herman Steen emphasizes this investment as a crucial step towards establishing Cortalix as a leader in nanobody applications.
Herman Steen, CEO of Cortalix, says, "This investment allows us to further refine our technology and prepare it for clinical applications. Our goal is to become a leading player in nanobody-based PET imaging, radiotherapy, and immunotherapy. This funding brings us a step closer to realising that vision."
Cortalix operates within the biomedical network of Northern Netherlands, collaborating with the LIFE Cooperative, University of Groningen, and UMCG, focusing on CAR-T cell therapy development.
Collection
[
|
...
]